Quinolinate differentiates between forebrain and cerebellar NMDA receptors.

Article date: 1991/2/26

PubMed ID: 1676371

Journal name: European journal of pharmacology (ISSN: 0014-2999)


The potency of N-methyl-D-aspartate (NMDA), ibotenate, L-glutamate and quinolinate for inhibiting [3H]L-glutamate binding to rat brain NMDA receptors was determined by quantitative autoradiography. In contrast to NMDA, ibotenate and L-glutamate, quinolinate more potently displaced binding in forebrain regions than in the cerebellum. Of all drug-region combinations, only quinolinate affinity in the cerebellum was best described by a two-affinity component model (Ki = 24 and 275 microM; 45% high affinity). The cerebellum appears to contain a unique quinolinate-insensitive NMDA receptor subtype.

Author List: Monaghan D T, Beaton J A

Publication Types: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.

Substances mentioned in the article: Glutamates; Quinolinic Acids; Receptors, N-Methyl-D-Aspartate; Ibotenic Acid; Glutamic Acid; N-Methylaspartate; Quinolinic Acid;

Mesh terms: Animals; Autoradiography; Binding, Competitive/drug effects; Brain Chemistry/drug effects; Cerebellum/drug effects; Glutamates/metabolism; Glutamic Acid; Ibotenic Acid/pharmacology; In Vitro Techniques; Kinetics; N-Methylaspartate/pharmacology; Quinolinic Acid; Quinolinic Acids/pharmacology; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate/drug effects;

1676371.txt · Last modified: 2018/11/20 14:26 (external edit)